claims in their present form, it also is submitted that the within amendments obviate the rejection. In particular, claims 26 and 29-31 have been cancelled. The subject matter of such claims is now presented in new method claims 40-44. Applicants note, in particular, that support for the utility recited in claim 40 "for selective apoptosis in cancerous cell lines" appears throughout the specification. (See, in particular, pages 70-72 of the present application.)

Reconsideration and withdrawal of the rejection are thus requested.

The Office Action further indicates that the drawings remain unacceptable. It is noted that Applicants earlier submitted replacement sheets for Figures 1, 3, 4, 8, 9, 17, 21, 22, 24, 28, 31, 32, 33, 34, 35, 36 and 37, in order to correct improper margins and to provide better legends, in accordance with the comments by the Draftsperson on the PTOL 948 form. Applicants do not wish to cancel the drawings as suggested in the Office Action. While it is unclear why the drawings remain unacceptable, it is respectfully submitted that Applicants will submit a set of formal drawings for the subject application following issuance of a Notice of Allowance.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,



Christine C. O'Day
(Reg. No.: 38,256)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Tel. (617) 439-4444

VERSION MARKED TO SHOW CHANGES

IN THE CLAIMS:

Claims 20-32 have been cancelled.

New claims 33-44 have been added.

33. A compound having the general formula (I):



wherein:

(i) R_1 represents an unsubstituted C_6 or C_{10} aryl group; or a C_6 aryl group substituted with Me or OMe;

(ii) A represents O, S or a sulfur atom oxidized to a sulfoxide;

(iii) the cyclic group labeled F represents an unsubstituted C_6 or C_{10} aryl or a C_5 heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and

(iv) Y represents the group



wherein R_2 and R_3 are independently hydrogen; or methyl or ethyl;

or Y represents the group CH_3, or $(CH_2)_2CH_3$ or an unsubstituted C_5 heteroaryl group having nitrogen as a heteroatom.

34. The compound of claim 33 wherein R_1 is an unsubstituted 1-naphthyl

group.

35. The compound of claim 33 wherein F is an unsubstituted phenyl group or an unsubstituted naphthyl or 2,3-pyridine.

36. The compound of claim 33 wherein R_1 and F represent a 1-naphthyl group and a 2,3-naphto-fused group, respectively.

37. The compound of claim 33 wherein Y is selected from the group consisting of CH_3 or $N(Me)_2$, NHMe or a 4-pyridine group.

38. A compound of claim 33 selected from the group consisting of:
4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
4[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d] [1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo [2,1-d][1,5]benzothiazepine, or
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-oxide.

39. A pharmaceutical composition comprising the compound of claims 33-38 and a pharmaceutically acceptable carrier.

40. A method for selective apoptosis in cancerous cell lines comprising administering to a subject in need thereof, a pharmaceutically effective amount of a compound of formula I



wherein:

(i) R_1 represents an unsubstituted C_6 or C_{10} aryl group; or a C_6 aryl group substituted with Me or OMe;

(ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;

(iii) the cyclic group labeled F represents an unsubstituted C_6 or C_{10} aryl or a C_5 heteroaryl group having nitrogen as a heteroatom or a phenyl group substituted with ethoxycarbonyl function; and

(iv) Y represents the group



wherein R_2 and R_3 are independently hydrogen; or methyl or ethyl;

or Y represents the group CH_3; or $(CH_2)_2CH_3$ or an unsubstituted C_5 heteroaryl group having nitrogen as a heteroatom; and

assessing the affects of the administration.

41. A method of claim 40 wherein the compound is selected from the group consisting of:

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,

7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,

4[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine,
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-Oxide.

42. The method of claim 40 wherein the subject is a human or animal.

43. The method of claim 40 wherein the cancerous cell lines are selected from the group consisting of leukemic T cell lymphoblast cells (Jurkat), promyelocytic leukemia cells (HL-60), T-cell leukemia cells (Hut-78), chronic myeloid lymphoma cells (CML), T lymphoblastoid cells (CEM), cervix carcinoma cells (HeLa) and human breast carcinoma cells (MCF-7).

44. The method of claim 43 wherein the chronic myeloid lymphoma cells are selected from the group consisting of LAMA, KYO.1 and K562 cell lines.